The mycophenolate mofetil, a prodrug of mycophenolic acid, is a new immunosuppressive drug with a specific mechanism of action consisting in the inhibition of T- and B-lymphocytes proliferation. A series of animal experiments showed efficiency of the mycophenolate mofetil administered in monotherapy or in combination with other immunosuppressants to prolong the survival of different allo- and xenotransplanted grafts. In clinical trials, the mycophenolate mofetil, cyclosporine, and steroids demonstrated high efficacy in the prevention of acute rejection in the solid allotransplanted organs. The mycophenolate mofetil seems to be a suitable candidate for the treatment of many other, e.g., autoimmune and inflammatory diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Differences and Similarities Between Children and Adults With Rhupus Syndrome.
Int J Rheum Dis
January 2025
Faculty of Medicine, Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey.
Aim: In this study, we aimed to evaluate and compare the characteristics of pediatric and adult rhupus patients.
Methods: Thirty pediatric patients with rhupus syndrome and 15 adult patients with rhupus syndrome were included in this study. Similarities and differences between both groups were evaluated.
First full intracorporeal robotic cystectomy and neobladder in a renal transplant recipient.
J Surg Case Rep
January 2025
UNICAEN, Urology and Transplantation Department, Normandie University, CHU de Caen, Avenue de la Côte de Nacre, Caen 14000, France.
The literature regarding robotic-assisted radical cystectomy in kidney transplant recipients is limited. We present the first reported case of robotic-assisted radical cystectomy with a full intracorporeal orthotopic neobladder in a kidney transplant recipient. A 36-year-old man was diagnosed with muscle-invasive urothelial carcinoma 12 years after kidney transplantation.
View Article and Find Full Text PDFCharacterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study.
Am J Clin Dermatol
January 2025
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.
Background: Cutaneous lupus erythematosus (CLE) is an autoimmune condition characterized by a wide range of clinical manifestations and limited treatment options. There is little research on the impact of commonly used diagnostic tests including antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) on disease course or responsiveness to treatment.
Objective: This single-center retrospective cohort study aims to address this gap by characterizing clinicopathological characteristics, patient demographics, and treatment response among patients with CLE.
Low-cost solid-state fermentation to improve mycophenolic acid synthesis.
Nat Prod Res
January 2025
Loyola Centre for Research and Development, Xavier Research Foundation, St. Xavier's College Campus, Ahmedabad, Gujarat, India.
Mycophenolic acid (MPA) is an immunosuppressive/antibiotic drug, biologically produced by the fermentation of Penicillium brevicompactum as its secondary metabolite using submerged (SmF) and solid-state (SSF) fermentation processes. In this study, the SSF of (MTCC 1999) was done in optimised conditions to enhance MPA yield. Substrates including basmati and non-basmati rice, barley, oats, cornflakes, rice bran, and wheat bran were 80% moistened and sterilised.
View Article and Find Full Text PDFImmunosuppressive therapy to treat newly diagnosed primary heart involvement in patients with systemic sclerosis: An Italian cardiac magnetic resonance based study.
Semin Arthritis Rheum
January 2025
Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Background: Primary heart involvement (pHI) is frequent in systemic sclerosis (SSc), and is associated with a poor prognosis. Therapeutic strategies to treat SSc-pHI are not yet defined.
Objectives: To evaluate the efficacy of immunosuppressive therapy on cardiac magnetic resonance (CMR) features in patients with CMR-proven SSc-pHI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!